Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
A high hematocrit can be both: it is a hallmark of polycythemia vera, yet it also thickens the blood in ways that raise clot, heart attack, and stroke risk, so one finding does not rule out the other. Many other causes also elevate hematocrit, including dehydration, smoking, sleep apnea, chronic lung or kidney disease, high altitude, and testosterone therapy, which is why a single lab value is never diagnostic on its own. Key clues such as JAK2 mutation testing, erythropoietin levels, spleen size, platelet and white cell counts, and symptoms like itching after showers, headaches, or ruddy skin help separate polycythemia vera from secondary causes, and those details are explained below. There are several important factors to consider before assuming which explanation applies to you, so review the complete answer below rather than the summary alone.
If your bloodwork came back with a high hematocrit and you are unsure whether it signals a blood disorder, a reversible cause, or a genuine clotting and stroke risk that needs urgent attention, a few minutes of structured questions can bring clarity fast. Take a free, instant, online symptom check to see which conditions best match your pattern, learn which follow-up tests are typically ordered, and understand how soon you should be seen.
Last reviewed for medical accuracy: 09/12/2026
Hematocrit measures the percentage of your blood made up of red blood cells. It’s a standard part of a complete blood count (CBC). When hematocrit is higher than normal, your blood becomes thicker. This can affect how well oxygen travels in your body and how easily blood flows through vessels.
Key normal ranges:
Values above these ranges signal high hematocrit, which deserves careful evaluation.
High hematocrit can originate from various factors:
Determining the root cause is crucial. Polycythemia vera needs specific treatments, while secondary causes may resolve by addressing the trigger.
High hematocrit alone doesn’t confirm PV. However, if your hematocrit stays elevated after correcting dehydration and other reversible factors, further tests are needed. PV signs often include:
Additional lab work and possibly a bone marrow biopsy help doctors make a definitive diagnosis.
Yes. Thickened blood can slow flow and increase clotting risk. Clots can block vessels in the brain, leading to a stroke. Specifically:
Studies show that every rise in hematocrit correlates with increased stroke risk, especially in those with cardiovascular risk factors or PV.
Many people with elevated hematocrit have no symptoms. When symptoms occur, they are often subtle or overlap with other conditions. Common high hematocrit symptoms include:
If you notice any of these, it’s worth discussing with a healthcare provider. Early detection can prevent complications.
Review Your Complete Blood Count
Check if your hematocrit is consistently high. One isolated reading may reflect dehydration or lab variation.
Assess Lifestyle and Medical Factors
Lab Testing
Imaging and Physical Exam
Treatment depends on the cause:
Polycythemia Vera
Secondary High Hematocrit
Lifestyle tips for everyone:
If you’re experiencing any high hematocrit symptoms or are simply curious about potential causes, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you gather information before speaking with your healthcare provider.
Link: free, online symptom check, using the doctor approved Ubie Symptom Checker
High hematocrit can be a warning sign of serious conditions like polycythemia vera or an increased stroke risk. It’s important not to delay professional evaluation. Always speak to a doctor about anything life-threatening or serious. They can order the right tests, interpret results accurately, and recommend treatment tailored to your needs.
(References)
* Monge CC, Whittembury J. Chronic mountain sickness. Johns Hopkins Med J. 1976 Dec;139 SUPPL:87-9. PMID: 1011412.
* Nigg C, Naumann UK, Käser L. [Thrombocytosis]. Praxis (Bern 1994). 2008 Apr 2;97(7):343-9; quiz 350-1. doi: 10.1024/1661-8157.97.7.343. PMID: 18548812.
* Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T, CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8. PMID: 23216616.
* Spivak JL. Polycythemia Vera. Curr Treat Options Oncol. 2018 Mar 7;19(2):12. doi: 10.1007/s11864-018-0529-x. Epub 2018 Mar 7. PMID: 29516275.
* Griesshammer M, Kiladjian JJ, Besses C. Thromboembolic events in polycythemia vera. Ann Hematol. 2019 May;98(5):1071-1082. doi: 10.1007/s00277-019-03625-x. Epub 2019 Mar 8. PMID: 30848334; PMCID: PMC6469649.
* Krečak I, Lucijanić M, Zekanović I, Holik H, Morić Perić M, Šupe M, Coha B, Gverić-Krečak V. Hematocrit to hemoglobin ratio as a prognostic marker in polycythemia vera. Wien Klin Wochenschr. 2022 Feb;134(3-4):110-117. doi: 10.1007/s00508-021-01967-z. Epub 2021 Nov 4. PMID: 34738212.
* Kremyanskaya M, Kuykendall AT, Pemmaraju N, Ritchie EK, Gotlib J, Gerds A, Palmer J, Pettit K, Nath UK, Yacoub A, Molina A, Saks SR, Modi NB, Valone FH, Khanna S, Gupta S, Verstovsek S, Ginzburg YZ, Hoffman R, REVIVE Trial Investigators. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. N Engl J Med. 2024 Feb 22;390(8):723-735. doi: 10.1056/NEJMoa2308809. PMID: 38381675.
* Khalilova F, Kerimov A. CLINICAL AND LABORATORY CHARACTERISTICS OF THE LATENT FORM OF POLYCYTHEMIA VERA. Georgian Med News. 2024 Jul-Aug;(352-353):101-105. PMID: 39441278.
* Pemmaraju N, Yu J, Vasudevan A, Qureshi H, Braunstein E, Chojecki A. Treatment patterns and blood count control in 10,112 patients with polycythemia vera. Expert Rev Hematol. 2025 Jul;18(7):529-536. doi: 10.1080/17474086.2025.2520316. Epub 2025 Jun 26. PMID: 40512071.
* Chew LP, Ginzburg YZ, Kirubamoorthy K, Lee SE, Lee JH, Modi NB, Khanna S, Dinh P, Valone F, Molina A, Gupta S. Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera. Leuk Res. 2025 Dec;159:108132. doi: 10.1016/j.leukres.2025.108132. Epub 2025 Oct 29. PMID: 41175501.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.